Comparing Interleukin 6 and Procalcitonin for Sepsis Detection in Burn Patients
Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients
This study is testing whether measuring Interleukin-6 can help doctors find sepsis in burn patients better than the usual test with procalcitonin.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 25 Years to 60 Years |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06915974 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of Interleukin-6 (IL-6) compared to procalcitonin in identifying sepsis and septic shock in burn patients. Patients admitted to the burn ICU will have blood samples taken on days 1, 3, 7, and 10 to measure levels of IL-6 and procalcitonin. The results will guide clinical decisions regarding treatment success and the timing of ICU discharge. The study follows a structured treatment protocol based on the burn ICU standards.
Who should consider this trial
Good fit: Ideal candidates are patients with acute burns covering 25% to 50% of total body surface area, admitted to the burn ICU within 24 hours of injury.
Not a fit: Patients with burns covering more than 50% or less than 25% of total body surface area, as well as those with autoimmune diseases or cancer, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved detection of sepsis in burn patients, potentially reducing mortality rates and ICU stay duration.
How similar studies have performed: Previous studies have shown varying success in using biomarkers like IL-6 for sepsis detection, but this specific comparison in burn patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence. * patients with burn percentage of 25% to 50% of total body surface area * patients with second to third degree burns * ASA 1 and ASA 2 patients Exclusion Criteria: * Burn percentage more than 50% or less than 25% of total body surface area * Having autoimmune diseases * Cancer patients * ASA 3 and ASA 4 patients
Where this trial is running
Cairo
- Ain Shams University — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Ahmed H Elsayed, M.B.B.CH — Anaesthesia, intensive care, and pain management resident Ain Shams University
- Study coordinator: Ahmed H Elsayed, M.B.B.CH
- Email: AhmedHanyAbdelfatah@med.asu.edu.eg
- Phone: +201016305451
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.